Prostate Cancer

The findings supported the accelerated approval of rucaparib for the treatment of men with metastatic castration-resistant prostate cancer who have a deleterious BRCA mutation and who have previously received androgen receptor-directed therapy and taxane-based chemotherapy.

This study found that implementation of the enhanced recovery after surgery pathway combined with prehabilitation programs can significantly change the postoperative course of patients.

In this study, investigators found that the hydrogel spacer has a favorable risk-benefit profile for patients receiving radiotherapy for prostate cancer.

This data may help to inform future recommendations for surveillance of BRCA1/2-associated cancers, according to researchers.

In this study, researchers observed no association between black race and the risk of SREs and overall mortality in men with bone metastatic castration-resistant prostate cancer.

Results of phase 3 CONDOR study could have a far-reaching impact on patients with prostate cancer.

The University of Southern California expert discusses next steps for the trial and how the recent results could impact the future of care for patients with prostate cancer.

Results showed that once daily relugolix established superiority over leuprolide and reduced the incidence of major cardiovascular events.

The study met its co-primary endpoint of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and whose tumors had PTEN loss.

Rencsok and colleagues found that the proportion of white participants in the clinical trials studied has primarily remained above 80% since 1990.

Researchers detailed methods and processes that may be useful for additional research and validation of computational hematoxylin and eosin staining deep learning models and the images generated by them.

Payment models with shared-savings components, such as the Oncology Care Model, may be associated with fewer visits and lower costs in certain cancer settings in the first year.

This study found that regional- and distant-stage prostate cancer incidence continues to increase in US men aged ≥50 years.

The FDA approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

A recent examination of older adults with cancer found accelerated losses in differing sarcopenia measures existed before and after a cancer diagnosis.

The FDA approved rucaparib for the treatment of adult patients with a deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.

The chairman of the Glickman Urological & Kidney Institute at the Cleveland Clinic provides commentary and an adjacent perspective to the Duke Cancer Institute report.

Experts from the Duke Cancer Institute outline their current approach to stratifying surgical management of patients with prostate cancer.

A recent study found that the proportion of men with high-risk prostate-specific antigen levels at diagnosis was decreased in association with Medicaid expansion states.

Olaparib was found to be associated with longer progression-free survival and improved measures of response and patient-reported end points than either enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer.

In a webinar, a multidisciplinary team from Duke Cancer Center came together to discuss the differences in treating patients with genitourinary cancer as a result of the COVID-19 pandemic.

A recent study led by led by King's College London and Public Health England examined 1.4 million patients of cancer via the National Cancer Registry and found that early GP referrals led to longer survival rates for patients.

The model was able to use data from each treatment cycle to estimate intratumor subpopulations and accurately predict the outcomes in each subsequent cycle.

Results from the trial showed a statistically significant and clinically meaningful improvement in overall survival with olaparib versus enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer selected for BRCA1/2 or ATM gene mutations.

A prognostic survival model, titled PROVIEW, was able to accurately predict changing cancer survival risk over time and may have the potential to be a useful prognostic tool that can be completed by patients.